A 3-year cohort study of the natural history of spinocerebellar ataxia type 6 in Japan by Kenichi Yasui et al.
Yasui et al. Orphanet Journal of Rare Diseases 2014, 9:118
http://www.ojrd.com/content/9/1/118RESEARCH Open AccessA 3-year cohort study of the natural history of
spinocerebellar ataxia type 6 in Japan
Kenichi Yasui1*, Ichiro Yabe2, Kunihiro Yoshida3, Kazuaki Kanai4, Kimihito Arai5, Mizuki Ito6, Osamu Onodera7,
Shigeru Koyano8, Eiji Isozaki9, Setsu Sawai4, Yoshiki Adachi10, Hidenao Sasaki2, Satoshi Kuwabara4,
Takamichi Hattori4, Gen Sobue6, Hidehiro Mizusawa11,12, Shoji Tsuji13, Masatoyo Nishizawa14 and Kenji Nakashima1Abstract
Background: Only a few prospective studies have determined which clinical symptoms and factors are associated
with the disease severity of spinocerebellar ataxia type 6 (SCA6). A multicenter longitudinal cohort study was
conducted to clarify both the natural history of SCA6 in Japan and the factors influencing disease progression.
Methods: Patients were consecutively recruited between 2007 and 2008. Scores from the Scale for the Assessment
and Rating of Ataxia (SARA) and Barthel Index (BI) were collected prospectively each year. Additionally, data from
the Japan intractable diseases research (IDR) registry were collected both retrospectively, from 2003 to 2006, and
prospectively, from 2007 to 2010. As a result, we were able to collect 3 years of retrospective data and 4 years of
prospective data during the course of 3 yearly visits.
Results: Forty-six patients were registered. The follow-up rate of the third year was 93%. The SARA scores worsened
significantly each year. Over 3 years, the decline of the SARA scores was 1.33 ± 1.40 points/year. The results of
multivariate analysis of the decline of the SARA score were not significant. The IDR scores correlated well with
the SARA and BI scores. Kaplan-Meier curves of 7 years of data from the IDR registry illustrated the correlation
between the ability to walk and the time course of the disease.
Conclusions: Information regarding the progression of ataxia and the decline in the activities of daily living
(ADL) in patients with SCA6 was obtained by a 3-year cohort study and a 7-year IDR study. The decline of the
SARA score of patients with SCA6 was 1.33 ± 1.40 points/year. The results elucidate the natural history of SCA6,
factors influencing disease severity, and utility of data from the IDR registry of Japan.
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The spinocerebellar ataxias (SCAs) are neurodegenerative
diseases characterized by oculomotor disturbances, dysarth-
ria, limb and truncal ataxia, gait disturbances, and additional
variable symptoms [1]. In the 1990’s, genetic mapping
studies in patients with autosomal dominant cerebellar
ataxias (ADCAs) identified 7 polyglutamine diseases:
SCA type 1 [SCA1], SCA2, SCA3, SCA6, SCA7, SCA17,
and dentatorubral-pallidoluysian atrophy [DRPLA] [2].* Correspondence: yasui@med.tottori-u.ac.jp
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unless otherwise stated.Although numerous studies have described the clinical
manifestations of the SCAs [2-4], very few prospective
studies have examined which clinical symptoms and fac-
tors are associated with disease severity. Knowledge of
the natural history of the SCAs is required to counsel
patients and to design interventional trials. One cohort
study of SCA, the European EUROSCA natural history
study, was a multicenter longitudinal study that included
526 patients with SCA1, SCA2, SCA3, and SCA6 [5-8].
A 2-year follow-up study of EUROSCA used several
scales, including the Scale for the Assessment and Rat-
ing of Ataxia (SARA), to describe disease progression
and identify factors that specifically affected this process
[8]. Recently, Ashizawa et al. reported the results of atd. This is an Open Access article distributed under the terms of the Creative
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the United States [9]. We designed a multicenter longi-
tudinal cohort study of the natural history of SCA6 in
Japan. Our study used the SARA and the Barthel Index
(BI). SCA6 was selected because of the high prevalence
of patients with this disease in Japan.
In Japan, the Ministry of Health, Labour, and Welfare
has established a national registry system for the survey
of ‘intractable diseases’ such as the SCAs [10,11]. The
Ministry is conducting a project that subsidizes the med-
ical expenses of patients with an ‘intractable disease’.
This project also supports research activities on these
diseases because effective treatments have not yet been
established and the affected patients have considerable
disabilities. Each year, patients with an ‘intractable dis-
ease’ submit a ‘clinical inquiry sheet,’ which is completed
by their physician, to the IDR. Since 2003, the inquiry
sheet for patients with an SCA has included 5 items
from the International Cooperative Ataxia Rating Scale
(ICARS) and 6 items from the BI [12,13]. The purposes
of the IDR registry are to provide financial support for
patients and investigate the patients’ clinical states; how-
ever, data from the present IDR registry have not yet
been utilized for longitudinal natural history studies.
The primary aims of this study were to longitudinally
and quantitatively investigate the clinical severity, dis-
ease progression, and natural history of SCA6, to iden-
tify factors that specifically affected disease progression
in a 3-year prospective study in Japan, and to compare
the results of this study with those of previous studies.
The secondary aim was to examine the reliability and
utility of the data collected by the Ministry of Health,
Labour, and Welfare’s national IDR registry.
Methods
Patient registration
The present study was performed at 8 centers (Hokkaido
University, Niigata University, Chiba University, National
Hospital Organization Chiba-East-Hospital, Tokyo
Metropolitan Neurological Hospital, Shinsyu University,
Nagoya University, and Tottori University) belonging to
the Research Committee for Ataxic Disease. This commit-
tee is part of the Ministry of Health, Labour, and Welfare
of Japan. The written informed consent form, which was
approved by the institutional review board of all centers
and by the Ethics Committee of the Tottori University
Hospital, was signed by all study participants. Patients
with SCA6 who were being treated at any of the 8 centers
were consecutively recruited between 2007 and 2008. A
linkable, anonymizing registration system was used to
register all patients.
The patients did not provide DNA samples for this
study and therefore diagnoses based on DNA analyses
were made in accordance with the protocols being usedat each center. Information regarding the CAG repeat
length of the expanded allele of the alpha 1A P/Q type
voltage-dependent calcium channel gene (CACNA1A) of
each patient was obtained from the medical records of
the respective center.Procedures of the 3-year prospective study
Registration and follow-up evaluations were performed
from April to July during the annual registration period
of the Japan IDR registry; therefore, follow-up investiga-
tions were performed at the same time each year. As
part of the prospective study, all patients were assessed
with the SARA and the BI each year. The SARA was
used to assess the degree of ataxia. The SARA consists
of 8 items: gait, stance, sitting, speech, finger chase,
nose-to-finger test, fast alternating hand movements,
and heel-to-shin slide. Each item has its own subscore.
The SARA grades ataxia on a scale of 0 to 40, with 0 in-
dicating the absence of ataxia and 40 indicating the most
severe degree of ataxia. The Japanese SARA is well vali-
dated and can be administered quickly [14,15]. The BI
was used to assess how well a patient performs the activ-
ities of daily living (ADL). The BI grades activity on a
scale of 0 to 100, with 0 indicating that a person cannot
care for him/herself and 100 indicating that a person
can care for him/herself. All investigators were board-
certified neurologists and were experienced in the use of
the applied scales.Procedures of the 7-year IDR registry study
The IDR inquiry sheet for patients with an SCA includes
5 items from the ICARS (walking, standing with eyes
open, body sway with feet together and eyes closed,
knee-tibia test of the worse foot, and finger-to-nose test
of the worse hand [decomposition and dysmetria]) and 6
items from the BI (feeding, bathing, grooming, dressing,
mobility, and stairs) [11-13]. The total number of points
obtained from the IDR inquiry sheet for the 5 items
from the ICARS and the 6 items from the BI was re-
ferred to as the IDR-ICARS and IDR-BI scores, respect-
ively. The IDR-ICARS grades ataxia on a scale of 0 to
26, with 0 indicating the least impaired condition. The
IDR-BI grades activity on a scale of 0 to 55, with 0 indi-
cating the most impaired condition. The 5 items of the
IDR-ICARS were selected because these subscores cor-
related well with disease duration in Japanese patients
with cerebellar ataxia [10].
The IDR inquiry sheet was last modified in 2003. For
the retrospective portion of the IDR registry study, we
collected the IDR inquiry sheets from 2003 onwards.
The inquiry sheets were collected from the patients’
medical records, starting in the year they registered for
the study. IDR data collection continued prospectively
Table 1 Demographic, genetic, and clinical characteristics





No. 46 23 23
Age at onset, y 48.0 ± 9.3 (31–66) 48.8 ± 10.0 47.2 ± 8.6
Age at registration, y 63.0 ± 9.6 (41–78) 64.4 ± 10.0 61.5 ± 9.2
Disease duration, y 15.0 ± 8.0 (3–40) 15.6 ± 7.5 14.3 ± 8.7
SARA score, points
(Range, 0–40)
15.9 ± 7.1 (4–33) 18.2 ± 6.2 13.6 ± 7.3*
BI score, points
(Range, 0–100)
77.4 ± 22.4 (15–100) 72.2 ± 23.0 82.6 ± 20.9
IDR-ICARS score, points
(Range, 0–26)
14.8 ± 6.0 (5–26) 16.6 ± 5.6 13.1 ± 6.1*
IDR-BI score, points
(Range, 0–55)




23.2 ± 1.4 (21–27) 23.2 ± 1.3 23.3 ± 1.6
Where applicable, the values are given as the mean ± standard
deviation (range).
Abbreviations: BI = Barthel Index; CACNA1A= alpha 1A P/Q type voltage-dependent
calcium channel gene; CAG = cytosine-adenine-guanine; ICARS = International
Cooperative Ataxia Rating Scale; IDR = Intractable Diseases Research; SARA = Scale
for the Assessment and Rating of Ataxia.
IDR-BI = total points of 6 items from the BI assessed by the IDR registry.
IDR-ICARS = total points of 5 items from the ICARS assessed by the
IDR registry.
aThree patients are homozygous for the expanded allele (repeat lengths: 20,
22, and 24). The mean ± standard deviation was applied for 43 patients
heterozygous for the expanded allele (22 male and 21 female patients).
*The scores of female patients were significantly lower than those of male
patients (P < .05, Mann–Whitney test).
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by analyzing a total of 7 years’ worth of data.
Data analysis
The differences between the scores obtained at registra-
tion and those obtained at each year’s evaluation were
referred to as the Δ scores, and the differences between
the scores obtained at registration and the scores ob-
tained at the last evaluation were referred to as the total
Δ scores. The total Δ/year was calculated by dividing the
total Δ score by the number of follow-up years.
Statistical analyses were performed with IBM SPSS
Statistics software version 19 (SPSS Inc., Chicago, IL).
The test results were considered significant at the .05
level. The Mann–Whitney test was used to compare the
clinical characteristics of the male and female patients.
Correlations between clinical scores and covariates were
tested by using the Pearson correlation test. Data for dis-
ease progression were analyzed by using the Friedman
test followed by post hoc Wilcoxon signed rank tests.
The rate at which patients became wheelchair dependent
was calculated from the data of the 7-year IDR registry
study by using the Kaplan-Meier method. The CAG re-
peat length of the normal CACNA1A allele of each pa-
tient could not be collected in this study; therefore, we
analyzed the repeat lengths of the expanded alleles, with
the exception of the repeat lengths of the 3 patients who
are homozygous for the expanded allele. For the cross-
sectional study, an analysis of covariance at registration
was performed with the SARA score as the dependent
variable and sex, age at onset, disease duration, and
CAG repeat length of the expanded CACNA1A allele as
independent variables. For the prospective study, an ana-
lysis of covariance was performed with the total ΔSARA/
year as the dependent variable and sex, age at onset, disease
duration, CAG repeat length of the expanded CACNA1A
allele, and SARA score at registration as independent vari-
ables. Age at registration was not included in the model, as
age at registration was recorded as the sum of age at onset
and disease duration. The test results were considered sig-
nificant at the .01 level for the multivariate analysis.
Results
Patient characteristics
The study population consisted of 46 patients with SCA6
who belonged to 44 families. The SARA and IDR-ICARS
scores of female patients were significantly lower than
those of male patients. Although the age at onset, age at
registration, and disease duration tended to be lower in fe-
male patients than in male patients, the differences were
not statistically significant. Similarly, although the BI and
IDR-BI scores of female patients tended to be higher than
those of male patients, the differences were not statisti-
cally significant (Table 1).Correlations between clinical scores and factors at
registration
A patient’s age at the time of registration and the duration
of his/her disease were correlated with clinical scores;
however, a patient’s age at the time of disease onset and
the CAG repeat length of the expanded CACNA1A allele
were not correlated with those scores (Table 2).
The patients’ IDR-ICARS and IDR-BI scores corre-
lated well with their SARA and BI scores, respectively
(Figure 1A, B). The correlation coefficients of the SARA
and IDR-ICARS scores and the BI and IDR-BI scores
were 0.89 and 0.93, respectively (P < .001). The BI scores
were inversely correlated with the SARA scores (R =−0.83,
P < .001). Patients with a SARA score of less than 10 points
maintained a high BI score. Conversely, among patients
with a SARA score of more than 10 points, those with a
higher SARA score had a lower BI score (Figure 1C).
The results of multivariate analysis of the patients’
SARA scores at the time of registration are presented in
Table 3. An analysis of covariance with the SARA score
as the dependent variable and clinical factors as inde-
pendent variables produced multivariate models that ex-
plained 39.5% of the variance of the SARA scores. The
SARA scores were influenced by sex, age at onset,
Table 2 Correlations between the SARA, IDR-ICARS, BI,
and IDR-BI scores and patients’ demographics
SARA IDR-ICARS BI IDR-BI
Age at onset NS NS NS NS
Age at registration 0.36b 0.43c −0.45c −0.57c
Disease duration 0.35b 0.45c −0.35b −0.44c
CAG repeat length of the
expanded CACNA1A allelea
NS NS NS NS
Correlation coefficients are presented.
Abbreviations: BI = Barthel Index; CACNA1A = the alpha 1A P/Q type
voltage-dependent calcium channel gene; CAG = cytosine-adenine-guanine;
ICARS = International Cooperative Ataxia Rating Scale; IDR = Intractable Diseases
Research; NS = not significant; SARA = Scale for the Assessment and Rating
of Ataxia.
IDR-BI = total points of 6 items from the BI assessed by the IDR registry.
IDR-ICARS = total points of 5 items from the ICARS assessed by the
IDR registry.
aData on the CAG repeat length were analyzed for 43 patients heterozygous
for the expanded allele.
bP < .05 (statistical analysis conducted with the Pearson correlation test).
cP < .01 (statistical analysis conducted with the Pearson correlation test).
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panded CACNA1A allele.Findings of the 3-year prospective study
The data obtained from the prospective study were used
to obtain information on disease progression. This infor-
mation is presented in Table 4 (5 right most columns).
During the 3-year follow-up period, 2 patients died and
1 patient dropped out. The causes of the 2 deaths were
suffocation and aplastic anemia. One untraceable patient
could not continue to visit because of his disability. The
follow-up rate of the third year was 93%. The total num-
ber of evaluations for the prospective study was 177.
The SARA scores worsened significantly each year. The
ΔSARA/year at the 1-, 2-, and 3-year follow-up evalua-
tions was 1.35 ± 1.70 (mean ± SD), 1.39 ± 1.39, and 1.24 ±
1.06 points/year, respectively. The total ΔSARA/year was
1.33 ± 1.40 points/year. The ΔSARA/year was 1.08 ± 0.92
points/year for male patients and 1.56 ± 1.71 points/year
for female patients. The difference of the ΔSARA/year be-
tween genders was not significant. Each year, the SARA
scores of patients who scored between 0 and 24.5 points
changed by similar amounts (ΔSARA/year = 1.48 ± 1.86
points/y), but the amount of change was smaller for pa-
tients with scores of more than 25 points (ΔSARA/year =
0.48 ± 1.42 points/y).
Among the subscores of the SARA scale, the sub-
scores for gait (Δ/year = 0.27 points/y), stance (Δ/year =
0.22 points/y), and fast alternating hand movements
(Δ/year = 0.24 points/y) were worse than the 5 other sub-
scores (sitting: Δ/year = 0.10 points/y, speech: Δ/year =
0.16 points/y, finger chase: Δ/year = 0.06 points/y, nose-
to-finger test: Δ/year = 0.10 points/y, heel-to-shin slide:
Δ/year = 0.10 points/y) at the third year. The results ofmultivariate analysis for the decline in the SARA score
were not significant.
Findings of the 7-year IDR registry study
The data from the 7-year IDR registry study were used to
analyze disease progression. The results of this analysis
are presented in Table 4 (last 4 rows). The ΔIDR-ICARS/
year of the prospective portion of the study (absolute
value 0.66 ± 1.28 points/y) was similar to that of the retro-
spective portion (absolute value 0.60 ± 1.59 points/y). The
IDR-ICARS scores changed linearly in the retrospective
and prospective portions of the study. The regression co-
efficient of the linear regression analysis was 0.63. Among
the subscores of the IDR-ICARS scale, the subscore for
walking (Δ/year = 0.23 points/y) was worse than the 4
other subscores (standing: Δ/year = 0.12 points/y, body
sway: Δ/year = 0.11 points/y, knee-tibia test: Δ/year = 0.05
points/y, and finger-to-nose test: Δ/year = 0.07 points/y) at
the third year.
Among the 46 patients with SCA6 who participated in
this study, 9 already used a wheelchair when they filed
their first IDR inquiry sheet. During the 7-year study
period of the IDR registry, 12 of the remaining 37 pa-
tients became wheelchair dependent. Figure 2 panels A
and B show the rates at which patients became wheel-
chair dependent. These rates are based on disease dur-
ation and age, respectively. All patients with a disease
duration of less than 8 years and patients who were
younger than 51 years could walk during the entire
study. During the course of the study, patients with a
disease duration of more than 9 years and patients who
were older than 52 years gradually became wheelchair
dependent. The medians of disease duration and age in
patients who needed to use a wheelchair were 24.0 years
(95% confidence interval [95% CI], 12.8 - 35.2 y) and
77.0 years (95% CI, 71.6 - 82.4 y), respectively. The 9 pa-
tients who were wheelchair dependent when they filed
their first IDR inquiry sheet had a disease duration of
more than 11 years and an IDR-ICARS score of more
than 17 points, and all were older than 56 years.
Discussion
This 3-year prospective study elucidated the quantitative
natural history of SCA6 in Japan. Although several pre-
vious studies have used a cross-sectional or retrospective
design to describe the clinical characteristics of SCA6
[16-18], ours is the first to use SARA and BI scores to
prospectively assess a Japanese cohort. Furthermore, this
study provides an accurate natural history of SCA6 be-
cause of the high follow-up rate. Our success was pos-
sible because the study was performed in 8 centers
belonging to the Research Committee for Ataxic Dis-
ease. This committee is part of the Ministry of Health,

















































Figure 1 Relationships between the clinical scales used by the
prospective study and by the IDR registry. (A) The relationship
between the IDR-ICARS and SARA scales. The IDR-ICARS scores
correlated well with the SARA scores (R = 0.892, P < .001, Pearson
correlation test). (B) The relationship between the IDR-BI and BI
scales. The IDR-BI scores correlated well with the BI scores (R = 0.928,
P < .001, Pearson correlation test). (C) The relationship between the
SARA and BI scales. The BI scores were inversely correlated with the
SARA scores (R =−0.828, P< .001, Pearson correlation test). Abbreviations:
BI = Barthel Index; ICARS = International Cooperative Ataxia Rating Scale;
IDR = Intractable Diseases Research; SARA= Scale for the Assessment and
Rating of Ataxia.
Yasui et al. Orphanet Journal of Rare Diseases 2014, 9:118 Page 5 of 8
http://www.ojrd.com/content/9/1/118investigations were performed at the same time each
year, during the annual registration period of the Japan
IDR registry.
Regrettably, one disadvantage of this study is that
DNA was not collected: only data for the CAG repeat
length of the expanded allele of the CACNA1A gene was
used in our analysis. We did not analyze the repeat
lengths of the patients who are homozygous for the ex-
panded CACNA1A allele. These data were collected
from the patients’ medical records. Given that the gen-
etic data of this study were partially limited, we empha-
sized the clinical courses of the patients.
The correlation analysis of the patients’ clinical scores
and clinical factors revealed that a patient’s age at the
time of registration and the duration of his/her disease
were correlated with the SARA score (Table 2). These
results and the corresponding correlation coefficients
are similar to those of previous reports [6]. Furthermore,
the results of this study clarified the correlation between
the SARA and BI scores (Figure 1C). Among the 46 par-
ticipants in this study, female patients tended to be
younger and have a shorter disease duration than male
patients; however, the differences were not statistically
significant. On the other hand, the SARA and IDR-
ICARS scores of female patients were significantly lessTable 3 Results of multivariate analysis for the SARA
score at registration
R2 P Effect Estimate SE β t P
0.395 .001
Intercept −45.558 21.830 n/a −2.087 .044
Sex −5.669 1.775 −.415 −3.194 .003
Age at onset .338 .117 .451 2.877 .007




2.132 .812 .421 2.627 .012
R2 = Coefficient of determination; β = standard coefficient.
Abbreviations: CACNA1A = alpha 1A P/Q type voltage-dependent calcium channel
gene; CAG = cytosine-adenine-guanine; n/a = not applicable; SARA = Scale for the
Assessment and Rating of Ataxia; SE = standard error.
Table 4 Time course of disease progression based on the SARA, BI, IDR-ICARS and IDR-BI scores
Follow-up year −4 −3 −2 −1 Registration 1 2 3 Total
N (follow-up rate%) 29 35 38 40 46(100) 44(96) 44(96) 43(93) 177*
Death, n 0 1 0 1 2
Withdrawal, n 0 1 0 0 1
SARA score, points 15.9 ± 7.1 16.8 ± 6.9a 18.2 ± 7.2a 19.1 ± 6.9a 17.5 ± 7.1
ΔSARA, points 0 1.35 ± 1.70 2.78 ± 2.78 3.73 ± 3.17 n/a
ΔSARA/year, points/y 0 1.35 ± 1.70 1.39 ± 1.39 1.24 ± 1.06 1.33 ± 1.40
BI score, points 77.4 ± 22.4 77.4 ± 22.3b 73.8 ± 23.7b 75.0 ± 23.2 75.9 ± 22.8
IDR-ICARS score, points 13.9 ± 5.9 13.7 ± 5.9 14.1 ± 6.0c 14.6 ± 5.7 14.8 ± 6.0 15.0 ± 5.4b 16.0 ± 5.7b 16.2 ± 5.6 14.9 ± 5.8
ΔIDR-ICARS, points −2.28 ± 3.59 −2.06 ± 3.27 −1.29 ± 2.98 −0.50 ± 2.32 0 0.59 ± 1.65 1.59 ± 2.34 1.77 ± 2.79 n/a
ΔIDR-ICARS/year, points/y −0.57 ± 0.90 −0.69 ± 1.09 −0.64 ± 1.49 −0.50 ± 2.32 0 0.59 ± 1.65 0.80 ± 1.17 0.59 ± 0.93 0.63 ± 1.45d
IDR-BI score, points 37.1 ± 14.0 38.6 ± 14.2 38.4 ± 13.8c 37.4 ± 14.1 36.7 ± 15.1 37.6 ± 15.0 34.9 ± 14.8b 35.8 ± 14.9 36.3 ± 14.9
Where applicable, the values are given as the mean ± standard deviation.
Comparisons of the IDR-ICARS, IDR-BI, SARA, and BI scores of each year were made by using the Friedman test followed by the Wilcoxon signed rank test as a post
hoc test.
Abbreviations: BI = Barthel Index; ICARS = International Cooperative Ataxia Rating Scale; IDR = Intractable Diseases Research; n/a = not applicable; SARA = Scale for
the Assessment and Rating of Ataxia.
IDR-BI = total points of 6 items from the BI assessed by the IDR registry.
IDR-ICARS = total points of 5 items from the ICARS assessed by the IDR registry.
ΔIDR-ICARS and ΔSARA = differences between the scores obtained at the follow-up evaluations and those obtained at registration for the IDR-ICARS and
SARA, respectively.
aP < .001, versus the previous year for the prospective study.
bP < .05 versus the previous year for the prospective study.
cP < .05 versus the next year for the retrospective study.
dTotal of the IDR-ICARS/year calculated with the absolute value of each ΔIDR-ICARS/year excluding that of the registration year.
*Total number of evaluations conducted during the prospective arm of the study.
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backgrounds differed slightly between genders.
During the 3 years of this study, the SARA scores de-
clined by 1.33 points/year, and the ΔSARA/year did not
change significantly. This decline in the SARA score is
greater than the 0.35 points/year decline that was ob-
served for the first year of the EUROSCA study but it is
similar to that observed for the second year (1.44 points/y)
[8]. In a study conducted in the United States, the SARA
score of patients with SCA6 declined by 0.87 ± 0.28 points/
year [9]. In another study conducted in Asia, the SARA
score of patients with SCA6 declined by 2.04 ± 0.76 points/
year [19]. Although the reason for these differences is
unclear, several explanations are possible. First, the
backgrounds of the patients may be an important fac-
tor. Second, the dependence of the ΔSARA on the
SARA score may be another reason why the scores dif-
fer: the ΔSARA/year for the patients with SARA scores
of 25 points or more was less than that for the patients
with SARA scores of less than 25 points. This finding
may have important implications for the design of fu-
ture clinical trials. Judging from the results of this
study, we conclude that it may be appropriate to ex-
clude patients with SARA scores of greater than 25
points. Third, the follow-up rate and the number of
patients enrolled may also have been associated with
the differences in the results of these studies.The results of multivariate analysis for the decline in
the SARA scores were not significant. The findings of a
2-year follow-up study by Jacobi et al. indicate that dis-
ease duration and CAG repeat length of the normal
CACNA1A allele were independent factors associated
with the decline in the SARA score in male patients with
SCA6 [8]. We currently have no explanation for Jacobi
et al’s study because the genetic data and number of pa-
tients of this study were limited. Disease progression in
patients with SCA6 may be affected by various factors
including disease duration, age, and disease severity at
the time of registration as well as by the CAG repeat
length of the CACNA1A alleles. The 3-year prospective
observation period of our study is longer than those of
previous studies, and the length of the observation
period is one of the most important factors for a study
of the natural history of a disease. Furthermore, as the
number of follow-up years increases, disease progression
may become increasingly homogenous.
In addition to data generated by the 3-year prospective
study, the 7-year IDR registry study provided long-term
information on the natural history of SCA6. The amount
of change of the IDR scores was small; therefore, the
IDR inquiry sheet may not be suitable for use in clinical
trials. However, the IDR inquiry sheet is simple and it
can be completed in the setting of a typical daily clinic.

























































Figure 2 Utilization of ADL states as milestones indicating
disease progression. Data from the 7-year IDR registry study was
used to obtain information regarding the time that elapsed before
patients became wheelchair dependent (A: Disease duration, B: Patient’s
age). Among 37 patients with SCA6, 12 became wheelchair dependent
during the 7 years of the study. The Kaplan-Meier curves are
shown. The medians (95% confidence interval) of disease duration
and age for those patients who became wheelchair dependent
were 24.0 years (12.8 – 35.2 y) and 77.0 years (71.6 – 82.4 y), respectively.
Abbreviations: ADL = activities of daily living; SARA = Scale for the
Assessment and Rating of Ataxia; SCA6 = spinocerebellar ataxia type 6.
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http://www.ojrd.com/content/9/1/118well with the SARA and BI scores, respectively. There-
fore, the IDR inquiry sheet could be useful for an un-
complicated follow-up study. The 7-year IDR registry
study allowed us to monitor the long-term progression
of ataxia, as indicated by the changes in the IDR-ICARS
scores and the decline in the ADL, which are measuredby the IDR-BI. Kaplan-Meier curves described the cor-
relation between the ability to walk and the time course
of the disease. A long-term period of observation is in-
dispensable for a thorough understanding of the natural
history of the SCAs.
Conclusions
This study clarified the natural history of SCA6 by per-
forming a 3-year prospective study and by analyzing
7 years’ worth of data from the IDR registry. The decline
of the SARA score of patients with SCA6 was 1.33 ±
1.40 points/year. Additionally, our study demonstrated
both the limitations and the advantages of Japan’s IDR
registry. Finally, the results of this study may have im-
portant implications for the planning of future clinical
trials that investigate new treatments for the SCAs.
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